<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5F600791-9929-4BAE-9186-DB9F207BD7C1"><gtr:id>5F600791-9929-4BAE-9186-DB9F207BD7C1</gtr:id><gtr:name>McGill University</gtr:name><gtr:address><gtr:line1>845 Sherbrooke Street W</gtr:line1><gtr:line4>Montreal</gtr:line4><gtr:line5>Quebec, H3A 2T5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1713C1F9-B8C3-45BD-BECD-471370A8838F"><gtr:id>1713C1F9-B8C3-45BD-BECD-471370A8838F</gtr:id><gtr:name>Complutense University of Madrid</gtr:name><gtr:address><gtr:line1>Ciudad Universitaria</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/102F2A51-71E4-4ECA-A245-9B9C4858D7E4"><gtr:id>102F2A51-71E4-4ECA-A245-9B9C4858D7E4</gtr:id><gtr:name>MRC Harwell</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>The Roslin Institute</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5F600791-9929-4BAE-9186-DB9F207BD7C1"><gtr:id>5F600791-9929-4BAE-9186-DB9F207BD7C1</gtr:id><gtr:name>McGill University</gtr:name><gtr:address><gtr:line1>845 Sherbrooke Street W</gtr:line1><gtr:line4>Montreal</gtr:line4><gtr:line5>Quebec, H3A 2T5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1713C1F9-B8C3-45BD-BECD-471370A8838F"><gtr:id>1713C1F9-B8C3-45BD-BECD-471370A8838F</gtr:id><gtr:name>Complutense University of Madrid</gtr:name><gtr:address><gtr:line1>Ciudad Universitaria</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/102F2A51-71E4-4ECA-A245-9B9C4858D7E4"><gtr:id>102F2A51-71E4-4ECA-A245-9B9C4858D7E4</gtr:id><gtr:name>MRC Harwell</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/158F0ED9-F4BC-4F6C-AA74-2062F00BC598"><gtr:id>158F0ED9-F4BC-4F6C-AA74-2062F00BC598</gtr:id><gtr:firstName>Barry</gtr:firstName><gtr:surname>McColl</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FL003384%2F1"><gtr:id>F4E6CE2E-0D17-43DC-A08B-73DF99318476</gtr:id><gtr:title>TREM-2, inflammation resolution and the transition from brain injury to repair after stroke</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L003384/1</gtr:grantReference><gtr:abstractText>Stroke is one of the most common causes of death and disability and is normally caused by a blockage in an artery carrying blood to the brain. Blockage of the artery triggers many processes that cause brain tissue to die and this leads to disability. Long term outcome after stroke and related brain disorders is influenced by the amount of initial brain damage and the capacity for surviving brain tissue to promote regeneration and repair. This is why understanding the factors that influence this balance between brain damage and repair after stroke is so important. Currently we have a poor understanding of this but recent research suggests that the immune system might be a crucial balancing influence.

The immune system produces an inflammatory response when the body is infected or injured, including when the brain is injured after a stroke. Research we and others have carried out previously in stroke patients and animal models of stroke has shown that inflammation can worsen brain damage and cause more disability. However, not all inflammation is bad because some brain repair processes are boosted by inflammation. These contrasting effects of inflammation mean that we need to find out how the bad, injury-causing effects of inflammation can be switched off without compromising the good effects of inflammation on brain repair and recovery. 

Our recent research has identified a chemical made by inflammatory cells that we believe could help control the balance between good and bad inflammation in the brain after stroke. This chemical is called TREM-2. The most exciting thing about TREM-2 is that it seems to affect this balance by limiting the injury-promoting affects of inflammation but at the same time still supporting responses of brain cells needed for repair. To potentially take advantage of these properties of TREM-2 in future we need to find out a lot more about how TREM-2 works under the conditions that occur in the brain after stroke. 

The overall aim of our research project is to build on our recent results and firmly establish how TREM-2 influences the balance of inflammation, injury and repair in the brain after stroke. To do this, we will address four key questions:
1. When and where is TREM-2 produced in the brain after stroke?
2. How does TREM-2 function affect the behaviour of inflammatory cells in the brain?
3. What effect does genetic deletion of TREM-2 have on inflammation, injury and repair?
4. What affect does boosting production of TREM-2 have on inflammation, injury and repair?

We expect that the answers to these questions will firmly show us if TREM-2 does limit injury-causing inflammation without compromising repair in the brain after stroke. More generally, the work will help us understand how the delicate balance of inflammation in the injured brain is controlled. Ultimately, we hope our findings can be used to help set up patient trials that will test if new treatments based on manipulating TREM-2 and more generally the balance of inflammation have potential to reduce death and disability in stroke patients.</gtr:abstractText><gtr:technicalSummary>Inflammation may have both damaging and protective influences during acute and chronic neurodegeneration including after acute cerebral ischaemia/stroke. This duality of inflammation underlines the need to understand how toxic and beneficial inflammation is balanced in the injured brain. In particular, establishing how pro-injurious inflammation can be contained or resolved without compromising the capacity for endogenous or exogenously-triggered brain repair is essential. 

Our recent data supporting this proposal show that Triggering Receptor Expressed on Myeloid cells-2 (TREM-2) may act as a critical molecular regulator restraining injurious inflammation and supporting repair e.g. we have shown that TREM-2 signalling in microglia and macrophages connects the removal of neurotoxic neutrophils with proliferation of neuronal precursors. However, the role of TREM-2 under the unique conditions of the ischaemic brain has not been studied previously.

The overriding aim of this proposal is to test the hypothesis that Triggering Receptor Expressed on Myeloid cells-2 (TREM-2) drives resolution of injurious inflammation and the transition from injury to repair in the brain after acute cerebral ischaemia. We will use a multi-modal approach including an experimental model of stroke, in vitro co-culture systems combining myeloid and neural cells and post-mortem brain tissue from stroke patients. We will exploit and generate novel tools that enable targeted deletion or augmentation of TREM-2 activity. These approaches will be used to determine expression patterns of TREM-2, the effects of TREM-2 on inflammatory cell phenotypes and the impact of TREM-2 deletion or overexpression on inflammatory profile and markers of injury and repair after stroke.

We expect our findings will provide a rational basis for developing effective immunomodulatory approaches for the treatment of stroke and other neurological conditions.</gtr:technicalSummary><gtr:potentialImpactText>Academic research - as described in the academic beneficiaries section, we expect multiple groups will benefit including those in the neurobiology/degeneration, stroke, immunology and bone disorder fields. This reflects the position of TREM-2 as a molecule that functions at the interface of basic neurobiology, neurodegeneration and immunology. These groups include those in the UK and internationally and include our collaborators. These groups will benefit through the increased knowledge and understanding our research will bring that will impact on their own ability to make advances in understanding related biological mechanisms and disease processes. The general biomedical community will also benefit through a major new resource we will create (TREM-2 overexpressing mouse) and our training of researchers in highly skilled and sought-after techniques, notably whole animal physiology.

University teaching and education - our research findings will inform teaching content and practices by providing up-to-date information on scientific advances leading to a more relevant teaching experience equipping students with better knowledge and skills

Clinical/healthcare - our project will benefit clinicians and healthcare providers through advancing knowledge on potential new strategies for treatment and management of stroke and related neurological disorders. These groups would be able to use the data we generate to inform decisions on testing agents in clinical trials in patients. Our project may also impact on general policy and practice in the long-term through generating new concepts on how stroke patients can be treated and managed e.g. by targeting mechanisms in the sub-acute phase.

Industry - a key aim of our proposal is to generate an evidence base for new therapeutic strategies and targets for stroke and related conditions. This information will benefit biotech and pharmaceutical companies by informing their drug discovery and development pathways. Reciprocal benefits are possible through partnerships with industry and investment by companies in academia

Schools - through our research projects and engagement activities we are able to promote the awareness of how scientific research contributes to addressing important issues related to health and wellbeing. This can benefit schools through enriching the science curriculum and providing opinion and advice to pupils and teachers on careers in biomedical research

General public - although our proposed research is at the discovery stage it has the potential to impact on the health and well-being of the general population through identifying new ways to treat many more individuals affected by stroke and related neurological conditions. The benefit may take years to realise however our research has the potential to contribute a vital step in this process. Our research will also generate opportunities to increase public awareness of science and its role in reducing suffering associated with injury and disease 

Policy makers - our work involves considerable use of in vivo approaches so has potential to generate new information influencing policy and practice relating to the use of animals in research</gtr:potentialImpactText><gtr:fund><gtr:end>2017-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>481382</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Bruce Whitelaw lab collaboration</gtr:description><gtr:id>A2B8E6AD-DD1C-46A6-9752-344B533DBEA8</gtr:id><gtr:impact>Funding application</gtr:impact><gtr:outcomeId>58c179505bb410.59295689-1</gtr:outcomeId><gtr:partnerContribution>Provision of technical and analytical expertise, creation of materials, sharing of data</gtr:partnerContribution><gtr:piContribution>Conducting experimental work, sharing of data, provision of technical and analytical expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>McGill University</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Sam David lab collaboration</gtr:description><gtr:id>E26861F5-A869-49E8-84F5-DCECA31B2375</gtr:id><gtr:impact>MTA and CDA put in place to enable formal collaboration and sharing of data and reagents</gtr:impact><gtr:outcomeId>58c17209874ca8.28846577-1</gtr:outcomeId><gtr:partnerContribution>Sharing of data and conducting studies using reagents provided by us</gtr:partnerContribution><gtr:piContribution>Sharing of data from our studies and provision of reagents under MTA</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Stuart Allan lab collaboration</gtr:description><gtr:id>777B4F04-A97B-4CB8-8FEB-D7A18CE682DF</gtr:id><gtr:impact>Publications
Funding applications</gtr:impact><gtr:outcomeId>58c173cedd1690.45502602-1</gtr:outcomeId><gtr:partnerContribution>Sharing of data, provision of technical and analytical expertise, proposing ideas for future studies</gtr:partnerContribution><gtr:piContribution>Sharing of data, provision of technical and analytical expertise, proposing ideas for future studies</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Colin Farquharson lab collaboration</gtr:description><gtr:id>283EC381-7908-43D5-B667-C238A5072ED0</gtr:id><gtr:impact>No outcomes yet</gtr:impact><gtr:outcomeId>58c179cba5c558.60620921-1</gtr:outcomeId><gtr:partnerContribution>Sharing of data, provision of technical and analytical expertise</gtr:partnerContribution><gtr:piContribution>Sharing of data, provision of technical and analytical expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Craig Smith collaboration</gtr:description><gtr:id>AEA97C52-FF49-4854-9F1F-15FFD0314A56</gtr:id><gtr:impact>Publication
Funding application submitted</gtr:impact><gtr:outcomeId>58c1753aeca1f1.57851960-1</gtr:outcomeId><gtr:partnerContribution>Sharing of data, provision of biological samples, provision of clinical expertise</gtr:partnerContribution><gtr:piContribution>Sharing of data, conducting experimental work using samples supplied by collaborator, provision of technical and analytical expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC Harwell</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC Mouse Network</gtr:description><gtr:id>420B975D-C337-4E4A-ACD3-CCD94C68E243</gtr:id><gtr:impact>Generation of mouse line</gtr:impact><gtr:outcomeId>5451fe9731e043.02896080-1</gtr:outcomeId><gtr:partnerContribution>Generation of knockout mouse line and phenotyping</gtr:partnerContribution><gtr:piContribution>Proposed genes to prioritise for phenotyping</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Complutense University of Madrid</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Alicia Garcia collaboration</gtr:description><gtr:id>F2B02932-B834-4F2E-89DB-7F3F31E4848A</gtr:id><gtr:impact>MTA and CDA</gtr:impact><gtr:outcomeId>58c176a39ce5a0.70191304-1</gtr:outcomeId><gtr:partnerContribution>Student placement, sharing of data, provision of technical and analytical expertise, conducting experimental work using reagents provided by us</gtr:partnerContribution><gtr:piContribution>Sharing of data, training of student, provision of technical and analytical expertise, provision of reagents under MTA, proposals for future research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>David Hume lab collaboration</gtr:description><gtr:id>57BE2130-D455-42A4-8742-9C67A96A49FA</gtr:id><gtr:impact>Publication
Funding applications submitted
MTA and CDA with other collaborators involved in studies</gtr:impact><gtr:outcomeId>58c177f9d57168.44987153-1</gtr:outcomeId><gtr:partnerContribution>Sharing of data, provision of technical and analytical expertise, conducting experimental work</gtr:partnerContribution><gtr:piContribution>Sharing of data, provision of technical and analytical expertise, conducting experimental work</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>McGill talk 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>54DA9C79-2493-45EC-BA60-A8E976D09D6B</gtr:id><gtr:impact>Talk presented as part of a symposium led to discussions and identifying common areas for collaboration with hosts - collaboration with Sam David lab initiated from this.</gtr:impact><gtr:outcomeId>58c2af49926376.80944300</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Roslin Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D51C4DCD-319E-4C67-8EBC-CE658878284D</gtr:id><gtr:impact>Institute Open Day to engage general public in our projects and broader research activities in the Institute. Visitors reported interest in learning about our work and why animals are necessary for some aspects of mediacl research</gtr:impact><gtr:outcomeId>583ff5a4d1b487.82263304</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Trinity College talk 2017</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D472DF97-946B-4BE0-B019-C0125DFF20DE</gtr:id><gtr:impact>Talk presented as part of a symposium enable dissemination of recent findings to a new audience. Discussion among fellow attendees also led to proposals for a joint consortium funding application</gtr:impact><gtr:outcomeId>58c2adfb394c24.46293883</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK Preclinical Stroke Symposium (Glasgow)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2A566B42-6044-431B-BAF6-6C52F6102139</gtr:id><gtr:impact>Oral presentations and discussion that enable dissemination of our data and led to revised opinions on the involvement of immune processes in stroke among the audience</gtr:impact><gtr:outcomeId>56d8142907dc99.75796508</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Symposium organiser/chair at BNA Festival of Neuroscience</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6233ED1C-936E-4ADC-87CA-AF91666F7965</gtr:id><gtr:impact>Organised and chaired a symposium at BNA conference - led to revised opinions on topic under discussion among presenters and audience</gtr:impact><gtr:outcomeId>56d81b665b1de3.95733211</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Neuroinflammation Keystone Symposium (New Mexico)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FF13D059-3241-4B14-9EA9-8C5700B87E33</gtr:id><gtr:impact>Presentations and discussion at international conference enabled wider recognition of our work and has resulted in new collaborations</gtr:impact><gtr:outcomeId>56d812d0362e82.85266856</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>75570</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Medical Research Foundation</gtr:department><gtr:description>MRF Equipment funding competition</gtr:description><gtr:end>2015-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>C0495</gtr:fundingRef><gtr:id>FCEE00B2-C946-4E41-A9E0-190059F0C248</gtr:id><gtr:outcomeId>5452005b62ec82.73274518</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5760</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>The Roslin Institute</gtr:department><gtr:description>Small Scale Project Grant</gtr:description><gtr:fundingOrg>University of Edinburgh</gtr:fundingOrg><gtr:id>F28A4A23-3C55-4D33-AC87-C884E771779B</gtr:id><gtr:outcomeId>58c17ef63efdc0.30379969</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1842</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Moray Endowment Fund</gtr:description><gtr:fundingOrg>University of Edinburgh</gtr:fundingOrg><gtr:id>EEE1C33F-BBCD-40B6-A271-131914BD0C2E</gtr:id><gtr:outcomeId>58c17e317c7273.06482253</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NC3Rs Stroke Working Group, Member</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>68A15C2F-95DF-4C49-AA93-1FADD2002849</gtr:id><gtr:outcomeId>54521797eeba30.84274742</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Spleen microarray datasets from experimental stroke study</gtr:description><gtr:id>5AFEE578-ECAD-4FAF-A039-041AF61EFBC9</gtr:id><gtr:impact>Not known</gtr:impact><gtr:outcomeId>58c2b56979def1.36984923</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>MCAO spleen datasets</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70841</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Microarray datasets</gtr:description><gtr:id>4828D7DD-B133-4B49-81B8-C7CCB7EF8A11</gtr:id><gtr:impact>Datasets have been used by other groups and their re-analysis of data included in publications</gtr:impact><gtr:outcomeId>58c2b49052d328.04918553</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Microglia datasets</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE62420</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>93F21E05-0449-4ABD-8E95-FCCE96AA70F3</gtr:id><gtr:title>Pro-death NMDA receptor signaling is promoted by the GluN2B C-terminus independently of Dapk1.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d3addfaa48f7ba5f876d53832ce6b19"><gtr:id>8d3addfaa48f7ba5f876d53832ce6b19</gtr:id><gtr:otherNames>McQueen J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>5aa28e80ab2aa2.78648737</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>702D390E-9344-4BB7-953F-8F8301A46C30</gtr:id><gtr:title>Minocycline reduces microgliosis and improves subcortical white matter function in a model of cerebral vascular disease.</gtr:title><gtr:parentPublicationTitle>Glia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/057115601fda0a015892fbd81aed28d7"><gtr:id>057115601fda0a015892fbd81aed28d7</gtr:id><gtr:otherNames>Manso Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0894-1491</gtr:issn><gtr:outcomeId>5aa28e7f809bf7.26535095</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F172DF84-9D90-46F6-B97B-5A000585AEBE</gtr:id><gtr:title>Requirement for interleukin-1 to drive brain inflammation reveals tissue-specific mechanisms of innate immunity.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e2bc98585046c8f8a7f2fe30bc72552"><gtr:id>4e2bc98585046c8f8a7f2fe30bc72552</gtr:id><gtr:otherNames>Giles JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>5451fc61a2b302.93028442</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D490BBD-BB26-473A-937B-325D8B3B9DA6</gtr:id><gtr:title>Microglial brain region-dependent diversity and selective regional sensitivities to aging.</gtr:title><gtr:parentPublicationTitle>Nature neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e6ae7d58b3f47002ea4e3da59ba8c46"><gtr:id>8e6ae7d58b3f47002ea4e3da59ba8c46</gtr:id><gtr:otherNames>Grabert K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1097-6256</gtr:issn><gtr:outcomeId>56d80ef37767c2.19513093</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E23CB20-D8AD-4424-8ADC-69F4AAB7025C</gtr:id><gtr:title>The MacBlue binary transgene (csf1r-gal4VP16/UAS-ECFP) provides a novel marker for visualisation of subsets of monocytes, macrophages and dendritic cells and responsiveness to CSF1 administration.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/740c6af898ac5a0f7fa20fd226968f91"><gtr:id>740c6af898ac5a0f7fa20fd226968f91</gtr:id><gtr:otherNames>Sauter KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5451fc166bf965.98476710</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFA00E29-3001-4200-8CC1-A5F4CC6866B9</gtr:id><gtr:title>The IMPROVE Guidelines (Ischaemia Models: Procedural Refinements Of in Vivo Experiments).</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2517bc6d8deeb5c6878a747ee03d16ac"><gtr:id>2517bc6d8deeb5c6878a747ee03d16ac</gtr:id><gtr:otherNames>Percie du Sert N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>5aa28e806ded69.28958523</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>491A5770-7568-449D-B41D-5ED0A9338A67</gtr:id><gtr:title>Corrigendum: Adrenergic-mediated loss of splenic marginal zone B cells contributes to infection susceptibility after stroke.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf9ca88eb9302095b0d8a372783d6bc3"><gtr:id>cf9ca88eb9302095b0d8a372783d6bc3</gtr:id><gtr:otherNames>McCulloch L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5aa28e808b7902.61180336</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>985F0774-13CD-4A91-BD35-C95D5092272C</gtr:id><gtr:title>Prolonged diet-induced obesity in mice modifies the inflammatory response and leads to worse outcome after stroke.</gtr:title><gtr:parentPublicationTitle>Journal of neuroinflammation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69e4075dcf805cade4de90af656b48d3"><gtr:id>69e4075dcf805cade4de90af656b48d3</gtr:id><gtr:otherNames>Maysami S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1742-2094</gtr:issn><gtr:outcomeId>56d80ef314a730.91058014</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2723523B-7A22-400E-97A0-B639441837EF</gtr:id><gtr:title>Neutrophil infiltration to the brain is platelet-dependent, and is reversed by blockade of platelet GPIba.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e2bc98585046c8f8a7f2fe30bc72552"><gtr:id>4e2bc98585046c8f8a7f2fe30bc72552</gtr:id><gtr:otherNames>Giles JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>5aa28e7fa6cff4.80034420</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>669A689D-8500-400A-9DC8-6007E81A254A</gtr:id><gtr:title>Defining the Microglia Response during the Time Course of Chronic Neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b4178e0339828a0d99625de1312863a"><gtr:id>0b4178e0339828a0d99625de1312863a</gtr:id><gtr:otherNames>Vincenti JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>56d80ef3451497.92199752</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44EB65AD-0243-4E56-ADE0-DA60FC9C7092</gtr:id><gtr:title>Corrigendum: Divergent Neuroinflammatory Regulation of Microglial TREM Expression and Involvement of NF-?B.</gtr:title><gtr:parentPublicationTitle>Frontiers in cellular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d24014b3aa5cdb463e7d0ef2ff28abe5"><gtr:id>d24014b3aa5cdb463e7d0ef2ff28abe5</gtr:id><gtr:otherNames>Owens R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1662-5102</gtr:issn><gtr:outcomeId>5aa28e80cb1c17.70958701</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D1E6711-626C-45E1-9864-B355FE09C38A</gtr:id><gtr:title>Divergent Neuroinflammatory Regulation of Microglial TREM Expression and Involvement of NF-?B.</gtr:title><gtr:parentPublicationTitle>Frontiers in cellular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d24014b3aa5cdb463e7d0ef2ff28abe5"><gtr:id>d24014b3aa5cdb463e7d0ef2ff28abe5</gtr:id><gtr:otherNames>Owens R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1662-5102</gtr:issn><gtr:outcomeId>58c16f9a3ab984.82821604</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7DF4A9FD-146B-4E6B-9F77-FE933D9146BA</gtr:id><gtr:title>Adrenergic-mediated loss of splenic marginal zone B cells contributes to infection susceptibility after stroke.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf9ca88eb9302095b0d8a372783d6bc3"><gtr:id>cf9ca88eb9302095b0d8a372783d6bc3</gtr:id><gtr:otherNames>McCulloch L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58c1702b039475.11187898</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L003384/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A77DAE3A-499B-4F46-971D-6C82F51F9C2E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Stroke</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>